This website uses cookies to offer services, collect data about the web traffic and to personalize advertisements. By using this website, you consent to the use of cookies.
More information

Medications used during the sterility treatment and methods of assisted reproduction

Oestrogens and progestogens are the main female sex hormones. They are commonly produced in the ovaries. Oestrogens are formed throughout the entire cycle, progestogens only in the second half of the cycle, after ovulation. Their main role is to work together to prepare the endometrium for implantation of the embryo.

In the field of assisted reproduction, in some cases the combination of oestrogens and progestogens is used to prepare the endometrium before the transfer of frozen embryos (FET). Progestogens alone are sometimes used after ovulation to support the preparation of the endometrium for embryo implantation or in the early stages of pregnancy, but also later in pregnancy to prevent premature delivery. However, it is always used in IVF cycle after egg retrieval to ensure the quality of the endometrium. We prefer agents with the effect as close to the natural hormones as possible.

Oestrogens may be in the form of tablets (Estrimax, Estrofem) adhesive plaster, spray or gel. Progestogens are administered orally; vaginal administration (Utrogestan, Gynprodyl, Crinone, Lutinus), or intramuscular (Agolutin) or subcutaneous (Prolutex) injections are more advantageous.

Ovulation in infertility treatment is often induced by antiestrogens (Clostilbegyt tbl, Tamoxifen tbl.). Their functioning is based on making use of feedback between oestrogens and gonadotropic hormones. Antiestrogens bind to oestrogen receptors and thereby induce production of gonadotropic hormones. They are always administered for a few days in the first half of the cycle.


To stimulate ovulation we use gonadotrophic hormones (gonadotrophins, GTH). They are formed naturally in the pituitary gland (hypophysis) and regulate the ovarian activity. GTH include the follicle-stimulating hormone (FSH) whose task is the growth of follicles, and luteinizing hormone (LH)whose task is maturation of follicles and induction of ovulation. Human chorionic gonadotrophin (HCG) is produced only during pregnancy by trophoblast and later by placenta. Detection of this hormone in blood or urine is used as a pregnancy test. For its structural similarity to LH it is used and produced, among other things, to trigger (start) ovulation (Pregnyl inj., Ovitrelle inj.).

We distinguish medications with only FSH effect, with only LH effect and with combined FSH + LH effect. Both types of products are used. Opinions on whether or when to use the product with a combined effect are not uniform. According to the method of production we distinguish the urinary-derived products, highly purified urinary-derived products and recombinant products.

The urinary-derived medicinal products have been on the market for the longest time, they always contain a certain amount of impurities and their effects are not completely constant (Merional amp., Menopur amp., Fostimon amp.).

Recombinant medicinal products are newer; they are produced by genetic engineering. They do not contain any impurities and the active substance content varies less than in urinary preparations. (Puregon Pen, Elonva inj., Gonal F Pen, Bemfola inj., Ovaleap Pen).

All gonadotrophin stimulation medications are applied subcutaneously by a thin needle and are therefore intended for self-administration. Most patients can do it without problems.

We use either small doses of gonadotrophins to induce maturation 1 or 2 follicles followed by IUI, or higher doses for controlled ovarian stimulation before IVF. We want to obtain more than one egg and consequently more than one embryo. This is achieved by administering gonadotrophins in relatively high doses. The dose depends on the results of hormonal profile, age, type of protocol, or weight, as the case may be.

In controlled hyperstimulation, it is not convenient that such substances are formed naturally in the woman’s body simultaneously with the administration of gonadotrophins. The thing is that it would be very difficult to harmonize their common action.

Therefore, in all ovarian stimulation protocols we use medicines that block the natural release of gonadotrophins from the hypophysis. They are called GnRh analogues. Under normal circumstances, the gonadotrophin releasing hormone (GnRh) is created in the part of brain called a hypothalamus. In the treatment, we do not use directly GnRh, but the substances originating from certain modifications of its molecule. We divide them into agonists and antagonists.

Shortly after their administration, agonists (Diphereline inj., Decapeptyl inj., Synarel spray) have the same effect as GnRH, and thus they increase the release of gonadotrophins from the pituitary gland, but later, thanks to their strong bonding, they block the pituitary receptors and inhibit the release of gonadotrophins. For this reason, agonists should be administered in the long term to make use of their blocking effect.

Antagonists (Cetrotide inj., Orgalutran inj.) have only a blocking effect; they can be therefore administered in the short term, during the stimulation itself.


There are certainly not all the preparations listed in our list. The reason for this is the fact that the situation in our market is constantly changing. The list will be continually updated.

Client ranking



Vážený pane doktore Šulci,

Chtěli bychom se touto cestou vrátit zpátky k péči, které se nám dostávalo od Vás a Vašich kolegů z GESTu od cca května loňského roku a které se nám dostává stále v průběhu prozatím dobře se vyvíjejícího těhotenství.

Vám bychom chtěli moc poděkovat mj. také za Váš přístup k nám, díky kterému jsme se i v ne vždy pozitivně vyhlížející situaci cítili tak, že je o nás postaráno a že je tady někdo, na koho se můžeme obrátit pro pomoc a radu. Moc si toho vážíme, protože nám to jednak pomohlo a také jsme si vědomi toho, že to v dnešní době bohužel stále není standard.

 Ještě jednou moc děkujeme



Finaly even me can boast with joyfull news. On 10th February 2020 was born gorgeous girl Michalka (3650 g, 51 cm). She arrived 10 days after predicted date of birth. We, happy parents, want to thank to the whole Gest team for the longwished happiness. Markéta and Lukáš



Finally can we show off our babyboy Michal. He was born on 24.12.2019, his weight was 2720g and was 48 cm long. Michal came into this world little bit earlier - at 37th week. 
Thanks a lot to the whole team - finally we have our little treasure. 
Happy parents Jaroslava and Luboš 



We would like to thank the whole GEST team for the birth of our babygirl Zuzanka. She was born on 13. 7. 2018. Her weight was just 1120g - she was early born (28+6 week). She became a healthy, beautifull girl.
Grretings and thanks a lot again. 
Milena Wágnerová  




We would like to thank to the whole GEST team for their care, namely Dr. Šulc, his colleagues, which we also met - Dr. Poláková, Dr. Černý and Dr. Alexandr. 
On 28th October was born our healthy babyboy Jakoubek. 
Thank you very much!
Jana and Martin 



We want to thank to the whole GEST team for their excellent care and kindliness. Because of them is our family bigger. On 30th September 2019 was our babyboy (4270g) born. 

Tomáš and Klára 

Contact form

Write to us

I agree that my contact information will be stored by the website provider in the extent necessary for the fulfillment of my request and will be forwarded to responsible third parties. I have read the statement on the processing of personal data on this site.

I agree to process my personal data

Where do you find us?


NL - CLINIC Gest IVF s.r.o.
Nádražní Str. 762/32
(entrance from Rozkošného Str. 1058/3)
150 00 Praha 5 - Smíchov

Surgery hours:

Mon - Fri

8 - 19 On Fridays is open only until 5pm 
Sat 8 - 13  


Phone.: +420 257 212 516 - 518
Mobile: +420 602 328 346
© 2017-2020, CLINIC Gest IVF s.r.o. All Rights Reserved. Created by S2 STUDIO